首页> 外文期刊>The Lancet >Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial.
【24h】

Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial.

机译:实施循证治疗方案以管理急性中风(QASC)中的发烧,高血糖和吞咽功能障碍:一组随机对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: We assessed patient outcomes 90 days after hospital admission for stroke following a multidisciplinary intervention targeting evidence-based management of fever, hyperglycaemia, and swallowing dysfunction in acute stroke units (ASUs). METHODS: In the Quality in Acute Stroke Care (QASC) study, a single-blind cluster randomised controlled trial, we randomised ASUs (clusters) in New South Wales, Australia, with immediate access to CT and on-site high dependency units, to intervention or control group. Patients were eligible if they spoke English, were aged 18 years or older, had had an ischaemic stroke or intracerebral haemorrhage, and presented within 48 h of onset of symptoms. Intervention ASUs received treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction with multidisciplinary team building workshops to address implementation barriers. Control ASUs received only an abridged version of existing guidelines. We recruited pre-intervention and post-intervention patient cohorts to compare 90-day death or dependency (modified Rankin scale [mRS] >/=2), functional dependency (Barthel index), and SF-36 physical and mental component summary scores. Research assistants, the statistician, and patients were masked to trial groups. All analyses were done by intention to treat. This trial is registered at the Australia New Zealand Clinical Trial Registry (ANZCTR), number ACTRN12608000563369. FINDINGS: 19 ASUs were randomly assigned to intervention (n=10) or control (n=9). Of 6564 assessed for eligibility, 1696 patients' data were obtained (687 pre-intervention; 1009 post-intervention). Results showed that, irrespective of stroke severity, intervention ASU patients were significantly less likely to be dead or dependent (mRS >/=2) at 90 days than control ASU patients (236 [42%] of 558 patients in the intervention group vs 259 [58%] of 449 in the control group, p=0.002; number needed to treat 6.4; adjusted absolute difference 15.7% [95% CI 5.8-25.4]). They also had a better SF-36 mean physical component summary score (45.6 [SD 10.2] in the intervention group vs 42.5 [10.5] in the control group, p=0.002; adjusted absolute difference 3.4 [95% CI 1.2-5.5]) but no improvement was recorded in mortality (21 [4%] of 558 in intervention group and 24 [5%] of 451 in the control group, p=0.36), SF-36 mean mental component summary score (49.5 [10.9] in the intervention group vs 49.4 [10.6] in the control group, p=0.69) or functional dependency (Barthel Index >/=60: 487 [92%] of 532 patients vs 380 [90%] of 423 patients; p=0.44). INTERPRETATION: Implementation of multidisciplinary supported evidence-based protocols initiated by nurses for the management of fever, hyperglycaemia, and swallowing dysfunction delivers better patient outcomes after discharge from stroke units. Our findings show the possibility to augment stroke unit care. FUNDING: National Health & Medical Research Council ID 353803, St Vincent's Clinic Foundation, the Curran Foundation, Australian Diabetes Society-Servier, the College of Nursing, and Australian Catholic University.
机译:背景技术:在多学科干预后,在医院入院后90天评估患者结果,这些患者患有基于急性卒中单元(华硕)的循证性发烧的发烧管理,患有循证的发烧管理。方法:在急性中风护理(QAC)的质量上,一个盲人集群随机对照试验,我们在澳大利亚新南威尔士州的随机(群集),立即访问CT和现场高依赖单位干预或对照组。如果他们辐注英语,患者均有资格,18岁或以上,患有缺血性卒中或脑内出血,并在48小时内呈现出症状的48小时内。干预华硕接受治疗方案来管理发烧,高血糖和吞咽功能障碍,以便与多学科团队建设研讨会进行解决,以解决实施障碍。控制华硕只接收了现有指南的删节版本。我们招募了预干预和后期后患者群体,以比较90天的死亡或依赖(修改的Rankin Scale [MRS]> / = 2),功能依赖性(Barthel指数)和SF-36身体和精神组件摘要分数。研究助理,统计学家和患者被审判群体掩盖。所有分析都是通过意图治疗来完成的。该试验在澳大利亚新西兰临床试验登记处注册(ANZCTR),数字ACTRN126080005633669。调查结果:ASUS随机分配给干预(n = 10)或控制(n = 9)。在6564年评估资格中,获得了1696名患者的数据(687次预介入;介入后1009例)。结果表明,无论中风严重程度如何,干预ASU患者在90天内的死亡或依赖于死亡或依赖于(MRS> / = 2),而不是对照ASU患者(236 [42%] 558例干预组559名患者vs 259对照组中的[58%] 449,P = 0.002;治疗6.4所需的数量;调整后绝对差异15.7%[95%CI 5.8-25.4])。它们还具有更好的SF-36平均物理成分摘要评分(在对照组中,干预组中的45.6 [SD 10.2],P = 0.002;调整后绝对差3.4 [95%CI 1.2-5.5])但在治疗组的死亡率(21%[4%]的558例中没有改善,对照组中的451例,P = 0.36),SF-36平均精神组件总结得分(49.5 [10.9]对照组的干预组Vs 49.4 [10.6]在对照组,p = 0.69)或功能依赖性(条形指数> / = 60:487 [92%] 532名患者中的380例[90%]的423名患者; P = 0.44) 。解释:实施发烧,高血糖和吞咽功能障碍的护士发起的多学科支持的基于证据的议定书,从中风单元排出后提供更好的患者结果。我们的调查结果显示了增加行程单元护理的可能性。资金:国家健康与医学研究委员会ID 353803,圣文森特诊所基金会,Curran基金会,澳大利亚糖尿病协会服务,护理学院和澳大利亚天主教大学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号